Cryo-Cell net income rises to $555,000 in FY26 Q2; revenue slips 2% to $7.8 million

Cryo-Cell International, Inc.

Cryo-Cell International, Inc.

CCEL

0.00
  • Cryo-Cell posted fiscal Q2 2026 revenue of USD 7.8 million, down 2% from the year-earlier quarter.
  • Net income rose to USD 555,000, or USD 0.07 per share, from USD 356,000, or USD 0.04 per share.
  • Processing and storage fee revenue slipped to USD 7.71 million; public banking revenue increased to USD 46,000.
  • Product revenue was flat at USD 14,000, while the quarter’s revenue decline was driven by lower processing and storage fees.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryo-Cell International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715354031) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.